Recommendations for antibiotic monitoring in ICU patients;Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 4, 2008, Pages 230-239

  Álvarez Lerma, Francisco ^a   Olaechea, Pedro ^b   Grau, Santiago ^a   Marín, Mónica ^a   Domínguez, Alfonso ^c   Martínez Lanao, José ^d   Soy, Dolors ^e   Alos, Manuel ^f   Calvo, María Victoria ^c   Sádaba, Belén ^g   Mediavilla, África ^h   Fatela, Daniel ⁱ  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Critically ill patient; Monitorization of antibiotics; Recommendations

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; VANCOMYCIN;

BLOOD SAMPLING; BLOOD VOLUME; CONFERENCE PAPER; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; PATIENT MONITORING;

EID: 42149127671     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/s0213-005x(08)72695-8     Document Type: Conference Paper

References (61)

1. Bailie GR, Mathews A. Quantitative assessment of serum concentration monitoring and dosage adjustment of aminoglycosides. Ther Drug Monit. 1988;10:292-5.
2. Highet VS, Forrest A, Ballow CH, Schentag JJ. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother. 1999;43 Suppl A:53-63.
3. Blondeau JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid and increase of resistance: mutant prevention concentration. J Chemother. 2004;16 Suppl 3:1-19.
4. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH. Pharmacodynamic evaluation of factors associated with development of bacteria resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998;42:521-7.
5. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:159-60.
6. Boucher BA, Word GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22:255-71.
7. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet. 2001;40:833-68.
8. Van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med. 1990;16 Suppl 3:S235-S238.
9. Álvarez-Lerma F, Grau S, Marín-Casino M, Olaechea P, Sánchez M, Martín E, et al, y GIPC-SEIMC. Monitorización de las concentraciones plasmáticas de antibióticos en hospitales españoles. Enferm Infecc Microbiol Clin. 2006; 24:14-9.
10. Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents. 2002;19:341-8.
11. Albanese J, Leone M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000;44:1356-8.
12. ATS/IDSA Lomas J. Words without action? The production, dissemination, and impact of consensus recommendations. Annu Rev Public Health. 1991;12:41-65.
13. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009-34.
14. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993;21:172-3.
15. Power BM, Forbes AM, Van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998;34:25-56.
16. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002;41:35-51.
17. Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care. 2002;30:134-44.
18. Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics & pharmacodynamics, principles of therapeutic drug monitoring. 4th ed. Baltimore: Lippincott, Williams & Wilkins; 2006.
19. Bauer L. Applied clinical pharmacokinetics. 1st ed. New York: McGraw-Hill; 2001.
20. Winter ME. Basic clinical pharmacokinetics. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2003.
21. Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. Clin Chemistry. 1998;44:1129-40.
22. Bergquist SC, Edmond MB. Vancomycin therapeutic drug monitoring in adult patients. P&T News: 1995. Disponible en: www.healthcare.uiowa.edu/pharmacy/ ptnews/1995/10.95.html .
23. Jacob S. Vancomycin monitoring: are both peak and trough levels necessary? CHRMC medication update newsletter; 2004.
24. Warner A, Biddinger P, Macpherson C, Retzinger G. Effective use of therapeutic drug monitoring: part 1. Timing issues. Lab Lines 1999;5.
25. Murphy JE. Clinical pharmacokinetics. 3rd ed. Bethesda: American Society of Health-System Pharmacists; 2005.
26. Tobin CM, Darville JM, Thomson AH, Sweeney G, Wilson JF, MagGowan AP, et al. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother. 2002;50:713-8.
27. Lee M. Basic skills in interpreting laboratory data. 3rd ed. Bethesda: American Society of Health-System Pharmacists; 2004.
28. Herman R. Current issues-related to therapeutic drug monitoring: vancomycin. World Drug Info. 2003;14:1-6.
29. Dhillon S, Kostrzewski A. Clinical pharmacokinetics. London: Pharmaceutical Press; 2006.
30. Smale F. Commentary: single daily dose of aminoglycoside is the preferred mode of administration. BMJ. 1996;312:344-5.
31. Barclay M, Kirkpatrick CMJ, Begg EF. Once daily aminoglycoside therapy: is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999;36:89-98.
32. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-5.
33. Dasgupta A, Blackwell W, Bard D. Stability of therapeutic drug measurement in specimens collected in VACUTAINER plastic blood-collection tubes. Ther Drug Monit. 1996;18:306-9.
34. Bailey DN, Coffee JJ, Briggs JR. Stability of drug concentrations in plasma stored in serum separator blood collection tubes. Ther Drug Monit. 1988;10:352-4.
35. Laboratory Corporation of America® Holdings and Lexi-Comp Inc.; 2003. Disponible en: http://www.labcorp.com/contact_us/index.html
36. a reimpresión. Vol. 1. Madrid: Síntesis; 2001. p. 355-89.
37. Martínez Lanao J. Conceptos en farmacocinética clínica. Capítulo 8. En: Herrera Carranza J, editor. Manual de farmacia clínica y atención farmacéutica. Madrid: Elsevier España; 2003. p. 143-74.
38. American Society for Testing and Materials. Use of bar codes on specimen tubes in the clinical laboratory. Philadelphia: ASTM; 1992. p. E1466-92. Disponible en: http://www.astm.org
39. Whisler K, Maffetone M, Watt S. Automated system for positive specimen identification and simple handling. Clin Chem. 1990;36:1587-8.
40. Weilert M, Tilzer LL.Putting bar codes to work for improved patient care. Clin Lab Med. 1991;11:227-38.
41. Sharpe PC, Morrow J, Trimble ER. An audit of therapeutic drug monitoring anticonvulsants. Ulster Med J. 1995;64:151-6.
42. Sadeg N, Francois G, Petit B, Dutertre-Catella H, Dumontet M. Automated liquid-chromatographic analyzer used for toxicology screening in a general hospital: 12 months' experience. Clin Chem. 1997;43:498-504.
43. Vogeser M. Liquid chromatography-tandem mass spectrometry-application in the clinical laboratory. Clin Chem Lab Med. 2003;41:117-26.
44. Jolley ME, Stroupe SD, Wang CJ. Fluorescence polarization immunoassay: I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin Chem. 1981;27:1190-7.
45. Rubenstein KE, Schneider RS, Ullman EF. "Homogeneous" enzime immunoassay: New immunochemical technique. Biochem Biophys Res Comun. 1972;47:846-51.
46. Cheng G, Bray K, Polito A. Nephelometric inhibition assay for gentamicin. Clin Chem. 1979;25:1078.
47. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-9.
48. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002;28:936-42.
49. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124:717-25.
50. Moise-Broder PA, Forrest A, Birmingham MG, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925-42.
51. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38:865-9.
52. Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusión. J Clin Pharm Ther. 2004;29:351-7.
53. Viladrich PF, Gudiol F, Linares J, Pallarés R, Sabaté I, Rufi G, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 1991;35:2467-72.
54. Martin C, Alaya M, Mallet MN, Viviand X, Ennabli K, Said R, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother. 1994;38:396-9.
55. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of a aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549-55.
56. Morris RG, Sallustio BC, Vinks AA, LeGatt DF, Verjee ZH, El Desoky E, et al. Some international approaches to aminoglycoside monitoring in the extended dosing interval era. Ther Drug Monit. 1999;21:379-88.
57. Bacopoulou F, Markantonis SL, Pavlou E, Adamidou M. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: Pharmacokinetics and associated outcomes. J Crit Care. 2003;18:107-13.
58. Disponible en: http://www.rxkinetics.com
59. Stevens DL. The role of vancomycin in the treatment paradigm. CID 2006;42 Suppl 1:S51-S57.
60. American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumoniae. Am J Respir Crit Care Med. 2005;171: 388-416.
61. Rybak MJ. The pharmacokinetic and pharmacodinamic properties of vancomycin. CID 2006;42:S35-S39.